GWP42003-P + Placebo

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Rett Syndrome

Conditions

Rett Syndrome, RTT

Trial Timeline

Jul 29, 2019 → Jan 21, 2021

NCT ID

NCT03848832

About GWP42003-P + Placebo

GWP42003-P + Placebo is a phase 3 stage product being developed by Jazz Pharmaceuticals for Rett Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT03848832. Target conditions include Rett Syndrome, RTT.

What happened to similar drugs?

3 of 8 similar drugs in Rett Syndrome were approved

Approved (3) Terminated (2) Active (3)

✅Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved

✅Esomeprazole + LansoprazoleAstraZenecaApproved

✅Esomeprazole MagnesiumAstraZenecaApproved

❌GWP42003-PJazz PharmaceuticalsPhase 3

❌trofinetideAcadia PharmaceuticalsPhase 3

🔄TrofinetideAcadia PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05288283	Phase 3	Terminated	Oct 31, 2022	Sep 28, 2023	Seizures Associated With EMAS
NCT04745026	Phase 2	Completed	May 31, 2021	Dec 21, 2023	Autism Spectrum Disorder
NCT04421456	Phase 2	Terminated	Aug 18, 2020	Mar 16, 2022	Schizophrenia
NCT03848832	Phase 3	Terminated	Jul 29, 2019	Jan 21, 2021	Rett Syndrome
NCT02607891	Phase 2	Completed	Nov 9, 2016	Oct 2, 2018	Epilepsy
NCT02544763	Phase 3	Completed	Apr 6, 2016	Feb 26, 2019	Tuberous Sclerosis Complex

Competing Products

20 competing products in Rett Syndrome

See all competitors

Product	Company	Stage	Hype Score
Esomeprazole + Aspirin + Rofecoxib	AstraZeneca	Approved	43
Esomeprazole + Lansoprazole	AstraZeneca	Approved	43
Esomeprazole Magnesium	AstraZeneca	Approved	43
AZD5213 and placebo	AstraZeneca	Phase 2	35
fingolimod (FTY720)	Novartis	Phase 1/2	32
PF-03654746 + Placebo + Placebo + PF-03654746	Pfizer	Phase 2	27
Aripiprazole	Bristol Myers Squibb	Pre-clinical	18
NBI-98854	Neurocrine Biosciences	Phase 2	24
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Phase 2	24
Valbenazine	Neurocrine Biosciences	Phase 2	32
NBI-98854	Neurocrine Biosciences	Phase 1	26
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Phase 2	32
NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
Valbenazine	Neurocrine Biosciences	Phase 2	32
NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
Abobotulinum toxin A	Ipsen	Pre-clinical	19
GWP42003-P	Jazz Pharmaceuticals	Phase 3	29
trofinetide	Acadia Pharmaceuticals	Phase 3	29
Trofinetide	Acadia Pharmaceuticals	Phase 3	37
Trofinetide	Acadia Pharmaceuticals	Phase 2/3	27